These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 1336343)

  • 21. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
    Croisier D; Chavanet P; Lequeu C; Ahanou A; Nierlich A; Neuwirth C; Piroth L; Duong M; Buisson M; Portier H
    J Antimicrob Chemother; 2002 Sep; 50(3):349-60. PubMed ID: 12205059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
    Drugeon HB; Juvin ME; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models.
    Knudsen JD; Odenholt I; Erlendsdottir H; Gottfredsson M; Cars O; Frimodt-Møller N; Espersen F; Kristinsson KG; Gudmundsson S
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2499-506. PubMed ID: 12878511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.
    Lacy MK; Nicolau DP; Banevicius MA; Nightingale CH; Quintiliani R
    J Antimicrob Chemother; 1999 Oct; 44(4):477-81. PubMed ID: 10588309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of four fluoroquinolones in an animal model of infected lung.
    Vallée E; Azoulay-Dupuis E; Pocidalo JJ; Bergogne-Bérézin E
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():39-44. PubMed ID: 1664828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.
    Yoshizumi S; Domon H; Miyazaki S; Yamaguchi K
    Antimicrob Agents Chemother; 1998 Apr; 42(4):785-8. PubMed ID: 9559783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
    Esposito S; Noviello S; Ianniello F
    Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic effect of oral levofloxacin, ciprofloxacin, and ampicillin on experimental murine pneumonia caused by penicillin intermediate Streptococcus pneumoniae for which the minimum inhibitory concentrations of the quinolones are similar.
    Ishida Y; Kurosaka Y; Murakami Y; Otani T; Yamaguchi K
    Chemotherapy; 1999; 45(3):183-91. PubMed ID: 10224340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
    Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1996 Feb; 40(2):362-6. PubMed ID: 8834881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance.
    Thorburn CE; Edwards DI
    J Antimicrob Chemother; 2001 Jul; 48(1):15-22. PubMed ID: 11418508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
    Frémaux A; Sissia G; Geslin P
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.
    Fukuda Y; Yanagihara K; Ohno H; Higashiyama Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Mizuta Y; Tashiro T; Kohno S
    Antimicrob Agents Chemother; 2006 Jan; 50(1):121-5. PubMed ID: 16377676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
    Azoulay-Dupuis E; Bédos JP; Mohler J; Peytavin G; Isturiz R; Moine P; Rieux V; Cherbuliez C; Péchère JC; Fantin B; Köhler T
    Antimicrob Agents Chemother; 2004 Mar; 48(3):765-73. PubMed ID: 14982762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice.
    Fukuoka T; Kawada H; Kitayama A; Koga T; Kubota M; Harasaki T; Kamai Y; Ohya S; Yasuda H; Iwata M; Kuwahara S
    Antimicrob Agents Chemother; 1998 Jan; 42(1):23-7. PubMed ID: 9449255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group.
    Aubier M; Verster R; Regamey C; Geslin P; Vercken JB
    Clin Infect Dis; 1998 Jun; 26(6):1312-20. PubMed ID: 9636854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolates.
    Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1996 Feb; 24(2):113-6. PubMed ID: 9147907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
    Klugman KP; Capper T
    J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci.
    Trautmann M; Ruhnke M; Borner K; Wagner J; Koeppe P
    Antimicrob Agents Chemother; 1996 Mar; 40(3):776-9. PubMed ID: 8851610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.